Humanigen, Inc. Overview
Pro stress-test →Humanigen is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. The company's lead candidate, lenzilumab, targets multiple therapeutic areas including CAR-T cell therapy toxicities, graft-versus-host disease, and severe infections.
Strategic Profile
Pro stress-test →Humanigen filed for Chapter 11 bankruptcy in January 2024 after the FDA declined emergency use authorization for lenzilumab in 2021. The company is now a subsidiary of Taran Therapeutics Inc. Despite regulatory setbacks, the company maintains a multi-indication pipeline with programs including ifabotuzumab for solid tumors and continues to pursue development of its proprietary Humaneered® antibody platform.
Competitive Landscape
Pro stress-test →Humanigen competes in the anti-GM-CSF monoclonal antibody space with Sesen Bio (SESn, niraparib+tebonatide combinations) and emerging CAR-T toxicity mitigation players. In the broader oncology/immunology domain, it faces competition from established tumor necrosis factor (TNF) inhibitors, newer IL-6 inhibitors, and CAR-T developers pursuing their own toxicity solutions. The company's clinical-stage status and financial distress significantly limit competitive positioning.
Industry Context
Humanigen, Inc. operates in Clinical-stage monoclonal antibody therapeutics.
Key facts
Founded: 2001 · Headquarters: Burlingame, California, US · Employees: 11-50 · Revenue: Estimated minimal to zero (clinical-stage post-bankruptcy) · Market cap: N/A (bankruptcy proceedings)